← Back to Search

Fatty Acid Supplement

C15:0 Supplementation for Metabolic Syndrome in Young Adults

N/A
Waitlist Available
Led By Jeffrey Schwimmer, MD
Research Sponsored by Jeffrey B. Schwimmer, MD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to 12 weeks

Summary

This trial will see if adding a type of saturated fat to one's diet affects their BMI.

Eligible Conditions
  • Metabolic Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to 12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to 12 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in plasma C15:0 levels
Secondary study objectives
Change in BMI
Change in High Sensitivity C-reactive protein
Change in Weight
+10 more

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: ActiveActive Control1 Intervention
200mg of pentadecanoic acid (C15:0) supplementation in capsules form
Group II: PlaceboPlacebo Group1 Intervention
Matching placebo in capsules form

Find a Location

Who is running the clinical trial?

Jeffrey B. Schwimmer, MDLead Sponsor
Jeffrey Schwimmer, MDPrincipal InvestigatorUC San Diego
1 Previous Clinical Trials
20 Total Patients Enrolled

Media Library

Supplement (Fatty Acid Supplement) Clinical Trial Eligibility Overview. Trial Name: NCT04947176 — N/A
Metabolic Syndrome Research Study Groups: Active, Placebo
Metabolic Syndrome Clinical Trial 2023: Supplement Highlights & Side Effects. Trial Name: NCT04947176 — N/A
Supplement (Fatty Acid Supplement) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04947176 — N/A
~7 spots leftby Dec 2025